Unnatural Products

Executive Summary

Unnatural Products (UNP) is a San Diego-based biotechnology company pioneering synthetic macrocyclic peptides to address historically undruggable targets. Founded in 2015, UNP's platform combines computational design and medicinal chemistry to create molecules with the specificity of antibodies and the oral bioavailability of small molecules, bridging the gap between biologics and traditional drugs. The company focuses on intracellular and extracellular targets across multiple therapeutic areas, with potential applications in oncology, immunology, and rare diseases. While UNP is private and early-stage, its innovative approach has attracted attention from investors and collaborators. The company has not yet disclosed specific funding rounds or clinical programs, but its technology could unlock a new class of therapeutics.

Upcoming Catalysts (preview)

• H2 2026Series A or B funding round closing70% success
• 2027Lead program enters preclinical development or IND-enabling studies60% success
• 2026-2027First major pharma partnership or licensing deal50% success